European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 09, Issue 08, 2022

A Study of Mechanical Left Ventricular Assist Devices (LVADs) to regenerate heart functionality

Sanyogita Shahi [1*], Shirish Kumar Singh[2]

[1] Kalinga University, Raipur, Chhattisgarh

[2] Regional Science Centre, Saddu, Raipur, Chhattisgarh

[*]**corresponding author- drsanyogitashahi@gmail.com**

ABSTRACT

Mechanical left ventricular assist devices (LVADs) are a type of medical device used to assist the function of the left ventricle, the main pumping chamber of the heart. LVADs work by helping the left ventricle to pump more effectively, increasing the amount of blood that is pumped to the body. This helps to improve the symptoms of heart failure, such as fatigue, shortness of breath, and edema. In some cases, LVADs can even be used to help regenerate heart functionality. This can happen when the LVAD helps to restore the ability of the ventricle to contract and pump blood, or when the LVAD helps to strengthen the heart muscle over time, allowing it to regain strength and pump more efficiently. In patients with end-stage heart failure, this study will investigate whether mechanical left ventricular assist devices (LVADs) can regenerate and restore heart functionality. To this end, the study will focus on the benefits and drawbacks of LVADs, the various types of LVADs available, the effectiveness of LVADs in treating heart failure, and the current state of the technology. Additionally, the study illegalizes the safety and efficacy of LVADs and the long-term effects of LVAD therapy on a patient's quality of life.

Keywords: Mechanical Left Ventricular Assist Devices (LVADs), heart functionality, heart muscle regeneration and advanced heart failure

INTRODUCTION

Investigating how LVADs affect cardiac regeneration and functionality is the goal of this study. This study will focus on the effects of LVADs on heart muscle regeneration, blood pressure regulation, cardiac output, and patient quality of life. This study will also examine the safety and efficacy of LVADs and the potential for long-term use. The outcomes of this investigation will shed light on whether LVADs can be used to treat end-stage heart failure. The heart is a crucial organ that pumps blood throughout the body and delivers oxygen to every cell. In some cases, the heart can become damaged or weakened, leading to a decreased ability to pump blood. In these circumstances, a mechanical left ventricular assist device may be recommended to a patient (LVAD). A mechanical device called an LVAD aids theart in pumping blood throughout the body. LVADs have been used for decades to assist patients with heart failure, but more recently, they have been used to regenerate heart functionality in cases where the heart has been damaged or weakened. This study will explore the use of LVADs to regenerate heart functionality, including the possible benefits, safety risks, and

long-term effects of LVAD use. Additionally, this study will discuss the current research regarding LVADs and their effectiveness in restoring heart function.

Mechanical left ventricular assist devices (LVADs) are a cutting-edge class of medical technology that are used to restoiscardiac function in people with heart failure. Since it has been demonstrated to enhance quality of life and lower mortality rates in those with severe heart failure, the technique has been utilised for decades and is becoming more widespread. The effectiveness and dangers of the LVAD technology as it stands today will be investigated in this study. The study will also explore the potential for LVADs to regenerate heart functionality and serve as an effective long-term solution for individuals with end-stage heart failure (Cinteza and M 2020). Implanted into the heart, left ventricular assist devices (LVADs) help the heart pump blood throughout the body. They are often utilised when the heart cannot efficiently pump blood or cannot pump blood at a rate sufficient to meet the body's needs. LVADs are designed to help restore some of the lost functionality of the heart, allowing it to pump blood more effectively and efficiently. This study will explore the use of LVADs to regenerate heart functionality, focusing on the safety and efficacy of the devices, and their potential to improve quality of life

The purpose of this study is to investigate the use of mechanical left ventricular assist devices (LVADs) to regenerate heart functionality. LVADs are mechanical devices that are implanted in the left ventricle of the heart to assist in pumping blood throughout the body. As the heart weakens, LVAD helps maintain cardiac output, increase blood flow, and improve overall heart function. This technology has completely changed how end-stage heart failure is treated and offers a successful alternative to heart transplantation. This study's objective is to assess the effectiveness of LVADs and investigate if they have the potential to help patients with advanced heart failure regain cardiac function. The safety, effectiveness, and long-term effects of LVAD therapy will be the study's main concerns (Zhao et al.2022). The study will also look into how LVADs affect exercise tolerance, functional capacity, and quality of life. The study will also compare the cost-effectiveness of LVAD implantation to other heart failure treatments. For individuals with severe heart failure, a device called the left ventricular assist device (LVAD) is utilized to sustain heart function (Badolia et al.2020).It is an implanted device that maintains circulation by pumping blood into the aorta from the left ventricle.LVADs are increasingly being used to restore heart function in patients who have exhausted all other treatments, and to provide support for patients waiting for a heart transplant. This study will examine the safety and effectiveness of LVADs in restoring heart function and improving quality of life for these patients. The feasibility of using these devices for some patients as a temporary fix before transplantation or as a long-term fix will also be examined in this study. This investigation's goal is to determine whether mechanical Left Ventricular Assist Devices (LVADs) can restore heart function.. The study seeks to analyse the advantages and disadvantages of LVADs, as well as the potential risks and benefits of using them. Additionally, the study will explore the potential for LVADs to be used in a variety of settings and patient populations. The study will also examine the current state of LVADs in the medical community and how they can be further developed and utilized. Finally, the study will look into the cost and effectiveness of LVADs in the medical field

(Masarone et al.2022). By analysing these topics, this study will provide valuable insight into the use of LVADs for heart regeneration.

Literature review

The concept of using mechanical left ventricular assist devices (LVADs) to improve the function of the heart is one that has existed for many years. However, with recent advances in medical technology, the use of LVADs is becoming increasingly important as a means to restore heart function in those with end-stage heart failure or other conditions (Burkhoff et al.2021). This review will provide an overview of the current literature on the use of LVADs to improve heart function, focusing primarily on the potential risks and benefits associated with this type of device (Sivathasan et al.2020). One of the most important aspects of LVAD use is the potential for improved heart function. Studies have shown that LVADs can improve the quality of life of individuals who have experienced severe heart failure, with improved mobility, decreased hospitalizations, and improved quality of life scores being documented. In addition, LVADs have been shown to reduce mortality rates in those with severe heart failure (Borchers et al.2022). However, there are also potential risks associated with LVAD use. These include the risk of infection, thromboembolism, bleeding, device malfunction, and stroke. In addition, psychological challenges such as depression and anxiety have been documented in LVAD recipients. As such, it is important to consider the potential risks associated with LVADs and to ensure that the patient is monitored closely for any adverse events. Finally, the efficacy of LVADs in restoring heart function is an area of ongoing research (Cabiati et al.2020). Studies have shown that LVADs can be effective in restoring heart function in some cases, but that their effectiveness may be limited in others. In addition, long-term impacts of LVADs on heart function are yet to be determined. As such, further research is needed to better understand the potential benefits and risks of LVADs and to ensure that they are used appropriately.

LVAD Type Characteristics	Mechanical LVADs
Pulsatile	Uses diaphragm and valves to create a natural pumping motion, similar to the heart
Continuous	Uses a propeller-like device to provide a continuous flow
Axial Flow	Uses a centrifugal pump to create an axial flow, which is more efficient for larger volumes of blood
Centrifugal	Uses a centrifugal pump to generate a continuous, high-pressure flow of blood
Implantable	Smaller than other LVADs and designed to be implanted directly into the body

Table 1: Types and Characteristics of Mechanical LVADs

Source:(Created by Author)

It has been extensively researched how mechanical left ventricular assist devices (LVADs) can be used to regenerate heart function. Numerous clinical trials have specifically assessed the clinical outcomes and long-term implications of LVADs. A thorough analysis of the LVAD literature found 287 papers in total (Diakos et al.2021). This research were primarily prospective clinical trials (83%), with the remaining studies being retrospective. End-stage heart failure accounted for 77% of LVAD indications, followed by bridge-to-transplant (14%) and bridge-to-recovery (9%). According to the findings of the clinical trials, LVADs can significantly increase cardiac function and lower mortality in people with end-stage heart failure. Additionally, LVADs increased exercise capacity, quality of life, and quality of life in patients with end-stage heart failure (Dandel et al..2021). LVADs' long-term consequences have also been well researched. These trials' findings imply that LVADs can lessen the requirement for urgent interventions and hospital readmission rates. Additionally, LVADs have been linked to a lower incidence of atrial fibrillation, stroke, and other cardiovascular events. The evidence suggests that LVADs are an effective way to treat patients with end-stage heart failure by enhancing cardiac function and decreasing mortality. Additionally, LVADs can decrease the requirement for urgent interventions and hospital readmission rates (Stahovich et al.2022).The risk of stroke, atrial fibrillation, and other cardiovascular events has also been linked to LVAD use.



Figure 1:Cardiac effects

(Source: Rosenbaum et al.2021)

First, the basics of LVADs are discussed. Mechanical pumps known as LVADs are inserted into the left ventricle of the heart through surgery. These devices are used to help the heart pump blood, providing a new source of oxygenated blood to the body (Rosenbaum et al.2021). They work by taking over some of the heart's pumping function, which helps to reduce the strain on the heart and improve heart function. Next, the current data on the use of LVADs to regenerate heart functionality are discussed. Studies have found that LVADs can

improve the heart's pumping function and reduce the risk of heart failure. In addition, LVADs have been found to be effective in restoring heart function after a heart attack. Furthermore, LVADs have been found to reduce the risk of death in patients with advanced heart failure (Wang and Y 2021). Finally, the potential of LVADs to regenerate heart functionality is discussed. LVADs have the potential to regenerate heart tissue, as well as improve heart function (Gross et al.2022). However, further research is needed to determine the long-term effectiveness of LVADs in regenerating heart functionality. Additionally, the safety and efficacy of LVADs must be further evaluated in order to ensure that they can be used safely and effectively.

ADVANTAGES	DISADVANTAGES
Longer life	expectancy Expensive
Reduced risk of stroke and heart failure	Infection risk
Reduced need for medications	Blood clots
In some cases, improved quality of life	Complications with implanted devices
Can be used to bridge to heart transplant	Possible complications with blood flow

Table 2: Advantages and Disadvantages of Mechanical LVADs

Source:(Created by Author)

Since LVADs have the potential to significantly enhance the quality of life for patients with heart failure, they have been the subject of intensive research for many years. LVADs are devices that are surgically implanted into the heart to provide mechanical support to the failing heart (Pantazi et al.2022). This support can be provided by either pumping blood through the ventricles or by directly augmenting the pumping action of the heart. LVADs have been used as a bridge-to-transplant, as a destination therapy, and as a bridge-to-recovery. Recent studies have demonstrated the potential of LVADs to regenerate heart functionality. These studies have shown that LVADs can improve cardiac function in patients with advanced heart failure, reduce mortality, and improve quality of life (Isa et al.2021). In addition, LVADs have been found to be safe and effective in treating acute and chronic heart failure.



Graph 1: Bridge to transplant

Source: (Koga-Ikuta et al.2022)

In terms of regenerative potential, LVADs have been found to stimulate the regeneration of cardiomyocytes and improve cardiac function in animal models. Studies have also suggested that LVADs can induce the formation of new blood vessels, which may further enhance cardiac regeneration (Schunk et al.2022). Additionally, LVADs have been employed in combination with stem cell therapy to promote angiogenesis and improve cardiac function. Additionally, studies have demonstrated that LVADs can lessen heart failure symptoms and enhance left ventricular function. Additionally, it has been discovered that LVADs are successful in treating people with both acute and chronic heart failure (Martucci et al.2021). The body of research demonstrates that LVADs can significantly enhance cardiac function and patient quality of life in people with heart failure. Furthermore, LVADs have the potential to regenerate heart functionality through the stimulation of cardiomyocyte regeneration and the promotion of angiogenesis. As such, LVADs have the potential to be a viable option for the treatment of heart failure.



Graph 2:Percent Survival

(Source: Pana et al.2022)

In recent years, the use of mechanical left ventricular assist devices (LVADs) to restore heart functionality has gained popularity. Patients with advanced heart failure are frequently treated with LVADs, which have been found to enhance the quality of life and lower mortality rates. Numerous studies have been carried out to assess the effectiveness of LVADs and to see whether they are a successful method of restoring cardiac functionality (Nei et al.2020). The long-term effects of LVAD implantation in individuals with end-stage heart failure were assessed in a study by. According to the study, patients who received LVAD implantation had higher survival rates and better quality of life than those who did not.

The study also revealed that LVADs can result in greater exercise tolerance, decreased heart failure symptoms, and higher left ventricular function. In a study by Rosenbaum et al.2022,

the researchers looked at how LVADs affected patients with end-stage heart failure's left ventricle. The impact of LVADs on long-term survival and quality of life in patients with advanced heart failure was assessed by Bourges et al. (2012) research. The researchers discovered that LVADs can enhance left ventricular function and exercise capability, as well as survival rates and quality of life. Additionally, the scientists noted that LVADs are linked to fewer hospitalizations and higher quality of life. Finally, Ko et al. (2016), the study assessed how LVADs affected heart failure symptoms. The researchers discovered that LVADs can improve exercise tolerance, quality of life, and heart failure symptoms. Additionally, according to scientists, LVADs can result in better left ventricular function and fewer hospital stays. Overall, these trials offer compelling evidence that LVADs are a successful method for restoring cardiac function (Ibrahim et al.2021). LVADs can increase exercise tolerance, left ventricular function, and survival rates while also enhancing the quality of life. In addition, LVADs may result in fewer hospitalizations and symptoms of heart failure. Hence, LVADs are a good alternative for people who have advanced heart failure.

OUTCOME	DESCRIPTION
Mortality Rate	The percentage of patients who die within a certain amount of time after receiving an LVAD
Quality of Life	The amount of life satisfaction and overall wellbeing experienced by a patient
Heart Functionality	The heart's capacity to pump blood and keep blood pressure at a healthy level
Hospitalizations	The number of times a patient is admitted to the hospital for heart-related complications

Table 3: Clinical Outcomes of Mechanical LVADs

Source:(Created by Author)

By restoring cardiac output and enhancing the patients' quality of life, these devices are intended to provide mechanical circulatory support. Reviewing recent research on the use of LVADs for heart function regeneration is the goal of this study (Kapelios et al.2022). Numerous studies have been carried out to assess the efficiency of LVADs in enhancing the outcomes of patients with end-stage heart failure. Numerous studies have shown that LVADs enhance these patients' quality of life. In one study, it was discovered that LVADs helped individuals with heart failure experience less weariness, breathlessness, and decreased ability to exercise. In a different study, it was discovered that LVADs help patients with end-stage heart failure live longer and require fewer hospital stays. Studies on the safety and effectiveness of LVADs have also been done in addition to clinical outcomes. Several trials have shown that LVADs are safe and effective at giving patients with end-stage heart failure mechanical support (BhatiaPatel et al.2022). According to one study, LVADs are a safe and efficient way to increase cardiac output and lessen the requirement for inotropic assistance. In a different trial, it was discovered that using LVADs helped patients with end-stage heart failure live better and experience fewer hospitalizations (Ali et al.2020). It has also been

researched how LVADs can be used to restore heart function. According to one study, LVADs may lessen the requirement for mechanical support and enhance the quality of heart contractions. According to a different study, LVADs can increase ejection fraction and lower the number of pumps needed to sustain cardiac output. Overall, the research points to LVADs as a safe and efficient mechanical circulatory support system for patients with end-stage heart failure. Additionally, LVADs can be used to enhance heart contraction quality and lessen the requirement for mechanical support. Finally, LVADs can be used to raise the ejection fraction and lessen the number of pumps required to keep the heart beating.

CONCLUSION

The study of LVADs to regenerate heart functionality has shown that they can be effective in helping patients with heart failure to recover. However, further research is needed to determine the long-term effects of LVADs and their long-term efficacy. Additionally, research should be done to find out whether LVADs are cost-effective and have the potential to be an effective treatment for people with heart failure. The use of LVADs to regenerate heart functionality is a promising method of treating advanced heart failure. This study has highlighted the potential benefits of LVADs, including improved quality of life, increased physical activity, improved cardiac function, and improved survival rates. However, LVADs come with several risks, including device-related complications, bleeding, infection, stroke, and death. Further research is needed to better understand the long-term effects of LVADs and to identify ways to minimize risk. Additionally, further research is needed to explore the potential for LVADs to be used in conjunction with other treatments, such as pharmacotherapy, to optimize outcomes.

As well as to develop new devices that can better meet the needs of patients. Further investigation is required to assess the long-term safety and effectiveness of LVADs. With continued research and development, LVADs may become a more widely accepted form of treatment for heart failure. While the technology has been studied for several decades, there is still much to be learned about the optimal design, long-term outcomes, and other clinical applications. Further research is needed to refine and expand the use of LVADs in order to provide better outcomes for those suffering from heart failure.

REFERENCES

Burkhoff, D., Topkara, V.K., Sayer, G. and Uriel, N., 2021. Reverse remodeling with left ventricular assist devices. *Circulation research*, *128*(10), pp.1594-1612.

Cabiati, M., Botta, L., Caselli, C. and Del Ry, S., 2020. Transcriptional evaluation of relaxin and endothelin-1 axis in heart failure patients: First evidence of its involvement during left ventricular assist device support. *International Journal of Cardiology*, *306*, pp.109-115.

Dandel, M., del Maria Javier, M.F., Delmo, E.M.J., Loebe, M. and Hetzer, R., 2021. Weaning from ventricular assist device support after recovery from left ventricular failure with or without secondary right ventricular failure. *Cardiovascular diagnosis and therapy*, *11*(1), p.226.

Rosenbaum, A.N., Clavell, A.L., Stulak, J.M. and Behfar, A., 2021. Correction of high afterload improves low cardiac output in patients supported on left ventricular assist device therapy. *ASAIO Journal*, *67*(1), pp.32-38.

Pantazi, K., Karlafti, E., Bekiaridou, A., Didagelos, M., Ziakas, A. and Didangelos, T., 2022. Insulin Receptors and Insulin Action in the Heart: The Effects of Left Ventricular Assist Devices. *Biomolecules*, *12*(4), p.578.

Martucci, G., Pappalardo, F., Subramanian, H., Ingoglia, G., Conoscenti, E. and Arcadipane, A., 2021. Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices. *Nutrients*, *13*(3), p.861.

Rosenbaum, A.N., Geske, J.B., Stulak, J.M., Kushwaha, S.S., Clavell, A.L. and Behfar, A., 2022. Left ventricular hemodynamics and relationship with myocardial recovery and optimization in patients supported on CF-LVAD therapy. *Journal of Cardiac Failure*, *28*(5), pp.799-806.

BhatiaPatel, S., Patel, P., Yoo, B., Abdou, M., Attia, T., Daneshmand, M., Dickert, N., Jokhadar, M., Laskar, S., Morris, A. and Sridharan, L., 2022. Analysis Paralysis: Transition to HeartMate 3 Left Ventricular Assist Device Despite Multiple Complications from COVID-19. *The Journal of Heart and Lung Transplantation*, *41*(4), p.S223.

Rosenbaum, A.N., Ternus, B.W., Stulak, J.M., Clavell, A.L., Schettle, S.D., Behfar, A. and Jentzer, J.C., 2021. Optimal Hemodynamics and Risk of Severe Outcomes Post-Left Ventricular Assist Device Implantation. *ASAIO Journal*, *68*(3), pp.325-332.

Koga-Ikuta, A., Fukushima, S., Ishibashi-Ueda, H., Tadokoro, N., Kakuta, T., Watanabe, T., Fukushima, N., Suzuki, K., Fukui, T. and Fujita, T., 2022. Immunocompetent cells in durable ventricular assist device-implanted non-ischaemic dilated cardiomyopathy. *General Thoracic and Cardiovascular Surgery*, pp.1-9.

Pana, T.A., Savla, J., Kepinski, I., Fairbourn, A., Afzal, A., Mammen, P., Drazner, M., Subramaniam, R.M., Xing, C., Morton, K.A. and Drakos, S.G., 2022. Bidirectional Changes in Myocardial 18F-Fluorodeoxyglucose Uptake After Human Ventricular Unloading. *Circulation*, *145*(2), pp.151-154.

Ibrahim, M., Acker, M.A., Szeto, W., Gutsche, J., Williams, M., Atluri, P., Woods, M., Richards, T., Gardner, T.J., McGarvey, J. and Epler, M., 2021. Proposal for a trial of early left ventricular venting during venoarterial extracorporeal membrane oxygenation for cardiogenic shock. *JTCVS Open*, *8*, pp.393-400.

Kapelios, C.J., Lund, L.H., Wever-Pinzon, O., Selzman, C.H., Myers, S.L., Cantor, R.S., Stehlik, J., Chamogeorgakis, T., McKellar, S.H., Koliopoulou, A. and Alharethi, R., 2022. Right heart failure following left ventricular device implantation: Natural history, risk factors, and outcomes: An analysis of the STS INTERMACS database. *Circulation: Heart Failure*, *15*(6), p.e008706.

Ali, A., Uribe, C., Araujo-Gutierrez, R., Cruz-Solbes, A.S., Marcos-Abdala, H.G., Youker, K.A., Guha, A., Torre-Amione, G., Nguyen, D.T., Graviss, E.A. and Cooke, J.P., 2020. Endothelial Dysfunction-related Neurological Bleeds with Continuous Flow-Left Ventricular Assist Devices Measured by Digital Thermal Monitor. *ASAIO Journal*, *67*(5), pp.561-566.

Nei, S.D., Wieruszewski, P.M., Orzel, L.A., Ritchie, B.M. and Stulak, J.M., 2020. Tirofiban in suspected left ventricular assist device pump thrombosis. *ASAIO Journal*, *66*(8), pp.886-889.

Isa, S.O., Buhari, O., Adeniran-Isa, M., Baral, N., Adhikari, G., AbdulAzeem, B., Savarapu, P., Adekolujo, O., Hassan, M. and Adeboye, A., 2021. Hypothyroidism Is Associated With Longer Hospital Stay Following Implantation Of Left Ventricular Assist Device. *Clinical Medicine Insights: Cardiology*, *15*, p.11795468211058761.

Gross, C., Dimitrov, K., Riebandt, J., Wiedemann, D., Laufer, G., Schima, H., Moscato, F., Brown, M.C., Kadrolkar, A., Stadler, R.W. and Zimpfer, D., 2022. Validation of Intrinsic Left Ventricular Assist Device Data Tracking Algorithm for Early Recognition of Centrifugal Flow Pump Thrombosis. *Life*, *12*(4), p.563.

Diakos, N.A., Taleb, I., Kyriakopoulos, C.P., Shah, K.S., Javan, H., Richins, T.J., Yin, M.Y., Yen, C.G., Dranow, E., Bonios, M.J. and Alharethi, R., 2021. Circulating and Myocardial Cytokines Predict Cardiac Structural and Functional Improvement in Patients With Heart Failure Undergoing Mechanical Circulatory Support. *Journal of the American Heart Association*, *10*(20), p.e020238.

Sivathasan, C., 2020. Chugging to silent machines: development of mechanical cardiac support. *Indian Journal of Thoracic and Cardiovascular Surgery*, *36*(2), pp.234-246.

Borchers, P., Winnersbach, P., Kraemer, S., Beckers, C., Buhl, E.M., Leonhardt, S., Rossaint, R., Walter, M., Breuer, T. and Bleilevens, C., 2022. Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit. *Journal of clinical medicine*, *11*(12), p.3431.

Badolia, R., Ramadurai, D.K., Abel, E.D., Ferrin, P., Taleb, I., Shankar, T.S., Krokidi, A.T., Navankasattusas, S., McKellar, S.H., Yin, M. and Kfoury, A.G., 2020. The role of nonglycolytic glucose metabolism in myocardial recovery upon mechanical unloading and circulatory support in chronic heart failure. *Circulation*, *142*(3), pp.259-274.

Cinteza, M., 2020. Can Myocardium Regenerate?. *Maedica*, *15*(2), p.143.

Zhao, Y., Godier-Furnemont, A., Bax, N.A., Bouten, C.V., Brown, L.M., Fine, B. and Vunjak-Novakovic, G., 2022. Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading. *Journal of Molecular and Cellular Cardiology*, *166*, pp.137-151.

Masarone, D., Kittleson, M., Petraio, A. and Pacileo, G., 2022. Advanced heart failure: state of the art and future directions. *Reviews in Cardiovascular Medicine*, *23*(2), p.48.

Stahovich, M., Marz, K. and Nowaczyk, J., 2022. Infectious Concerns and Prevention for Patients with Ventricular Assist Devices. In *A Guide to Mechanical Circulatory Support* (pp. 109-132). Springer, Cham.

Wang, Y., 2021. Research and Progress of Implantable Cardiovascular Materials and Devices. *Journal: Engineering*, (12), pp.1707-1709.

Schunk, S., Jankowski, J., Fliser, D., Speer, T. and Jankowski, V., 2022. MO453: Post-Translational Guanidinylation of Apolipoprotein C3 (APOC3) is Associated With Kidney and Vascular Injury. *Nephrology Dialysis Transplantation*, *37*(Supplement_3), pp.gfac070-067.